WY-14643, a novel antiplatelet and antithrombotic agent targeting the GPIb α receptor

Hypolipidemia and platelet activation play key roles in atherosclerotic diseases. Pirinixic acid (WY-14643) was originally developed as a lipid-lowering drug. Here we focused on its antiplatelet and antithrombotic abilities and the underlying mechanism.

Source: Thrombosis Research - April 14, 2024 Category: Hematology Authors: Chen Cao, Qingyuan Yang, Xiaoshuang Xia, Zhuangzhuang Chen, Peilin Liu, Xiaowen Wu, Hu Hu, Zhongren Ding, Xin Li Source Type: research